Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
20201.2k citationsDeepak L. Bhatt, Michael Szarek et al.New England Journal of Medicineprofile →
Clopidogrel with or without Omeprazole in Coronary Artery Disease
2010794 citationsDeepak L. Bhatt, Byron Cryer et al.New England Journal of Medicineprofile →
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
2020789 citationsDeepak L. Bhatt, Michael Szarek et al.New England Journal of Medicineprofile →
Predominance of Isolated Systolic Hypertension Among Middle-Aged and Elderly US Hypertensives
2001511 citationsGilbert L’Italien, Pablo Lapuerta et al.profile →
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
2017305 citationsSatish K. Garg, Phillip Banks et al.New England Journal of Medicineprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Pablo Lapuerta
Since
Specialization
Citations
This map shows the geographic impact of Pablo Lapuerta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo Lapuerta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo Lapuerta more than expected).
This network shows the impact of papers produced by Pablo Lapuerta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo Lapuerta. The network helps show where Pablo Lapuerta may publish in the future.
Co-authorship network of co-authors of Pablo Lapuerta
This figure shows the co-authorship network connecting the top 25 collaborators of Pablo Lapuerta.
A scholar is included among the top collaborators of Pablo Lapuerta based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Pablo Lapuerta. Pablo Lapuerta is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Bhatt, Deepak L., Michael Szarek, Bertram Pitt, et al.. (2020). Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine. 384(2). 129–139.789 indexed citations breakdown →
4.
Bhatt, Deepak L., Michael Szarek, Philippe Gabríel Steg, et al.. (2020). Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine. 384(2). 117–128.1204 indexed citations breakdown →
Weickert, Martin O., Gregory Kaltsas, Dieter Hörsch, et al.. (2018). Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs : Analysis of the Completed TELESTAR Extension Period. Pancreas. 47(3). 341–342.2 indexed citations
9.
Dillon, Joseph S., Matthew H. Kulke, Marianne Pavel, et al.. (2018). Time to Sustained Improvement in Bowel Movement Frequency With Telotristat Ethyl : Analysis of the Phase 3 TELESTAR Study. Pancreas. 47(3). 337–338.2 indexed citations
10.
Pavel, Marianne, Marta Benavent, M. Caplin, et al.. (2017). Efficacy and Safety Results of Telotristat Ethyl in Patients With Carcinoid Syndrome During the Double-blind Treatment Period of the TELECAST Phase 3 Clinical Trial. Pancreas. 46(3). 434–435.5 indexed citations
11.
Hoersch, Dieter, Michael Kulke, Emily K. Bergsland, et al.. (2016). Patient Interviews in TELESTAR, a Phase 3 Study of Telotristat Etiprate, Report Meaningful Improvement in Carcinoid Syndrome. Neuroendocrinology. 103. 89–89.1 indexed citations
12.
Kulke, Matthew H., Dieter Hoersch, Martyn Caplin, et al.. (2016). Telotristat etiprate shows benefit in treating patients With carcinoid syndrome that is inadequately controlled by somatostatin analog therapy in the phase 3 TELESTAR clinical trial. Pancreas. 45(3). 478–478.1 indexed citations
13.
Anthony, Lowell, Dieter Hoersch, Matthew H. Kulke, et al.. (2016). Assessing Treatment Benefit of Telotristat Etiprate in Patients with Carcinoid Syndrome : Patient Exit Interviews. Pancreas. 45(3). 470–470.1 indexed citations
Paramore, L. Clark, et al.. (2001). Impact of poorly controlled hypertension on healthcare resource utilization and cost.. PubMed. 7(4). 389–98.68 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.